|Day Low/High||82.75 / 83.22|
|52 Wk Low/High||72.30 / 94.19|
Here are two I think will bounce back before the end of the year.
The pharmaceutical giant's American depository receipts jumped on the heels of a report that the company's chairman is mulling a breakup of the firm.
Drug pricing remains front and center as healthcare companies start reporting quarterly results.
The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.
These names are showing bullish or bearish reversal patterns over the past week.
- Galaxies of Hope offers a unique digital experience that engages users through the art of visual storytelling to connect with others to understand NET cancer - Using real-life stories and voices of patients, caregivers, and physicians in the NET...
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Adamis' device to treat allergic reactions should compete effectively with Mylan's popular EpiPen, according to an analyst.
Stocks ended slightly higher Friday, after giving up most of the day's gains in the final minutes of trading.
The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
U.S. stock futures are rising Friday and global stocks rebound on strong gains in China; Deutsche Bank is higher even after receiving a fresh rebuke from the Fed over 'critical deficiencies' in its financial planning; Nike's sales in North America bounce back.
Happy Friday! These are the stories you must know ahead of the opening bell.
-- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)
A healthcare bill supported on both sides of the aisle was held up until Sen. Chuck Grassley talked with pharma companies.
Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.
President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.
Following up on President Trump's drug pricing speech last week, the FDA posted a list of 39 name-brand drug firms that are allegedly making life tough on generic drug companies.
Here's what you need to know now for Friday, May 18.
Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.
Last week, the Swiss drug giant's $1.2 million in payments to President Trump's fixer Michael Cohen became public. Now the government of Switzerland as well as two U.S. senators are looking into them.
U.S. stock futures are slightly higher Friday as Wall Street prepares for the Trump administration's North Korea summit and China trade talks. AT&T and Novartis pick up the pieces. JPMorgan overhauls stock trading.
Pharma giant Novartis is now immersed in the muck that is the Trump-Russia probe thanks to $1.2 million in payments to a shell company created by President Trump's fixer Michael Cohen.
U.S. stock futures are higher Wednesday morning as Wall Street digests President Trump's decision to exit the Iran deal. Disney beat on the top and bottom line, while Facebook is making major changes to its executive leadership.
The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.
The drugmakers and health insurer are preparing to unveil first-quarter numbers.
The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.